Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 15/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8938937 | 1.00 | ABCC9 (0.65) | ABCC9ABCB1 | |
| SCHEMBL13970141 | 1.00 | ABCC9 (0.65) | ABCC9ABCB1 | |
| SCHEMBL8983497 | 0.94 | ABCC9 (0.62) | ABCC9ABCB1 | |
| SCHEMBL8983583 | 0.94 | ABCC9 (0.62) | ABCC9ABCB1 | |
| SCHEMBL8983483 | 0.94 | ABCC9 (0.62) | ABCC9ABCB1 | |
| SCHEMBL8983485 | 0.94 | ABCC9 (0.62) | ABCC9ABCB1 | |
| SCHEMBL8983452 | 0.91 | ABCC9 (0.57) | ABCC9ABCB1 | |
| SCHEMBL8983455 | 0.91 | ABCC9 (0.57) | ABCC9ABCB1 | |
| SCHEMBL8983468 | 0.91 | ABCC9 (0.57) | ABCC9ABCB1 | |
| SCHEMBL8983539 | 0.91 | ABCC9 (0.57) | ABCC9ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0501797-B1 | Pyranyl cyanoguanidine derivatives | SQUIBB & SONS INC (US) | 1996-06-05 | — | — | EP | claimed |
| EP-0624589-A2 | Intermediates useful in the preparation of pyranyl cyanoguanidine derivatives and methods of preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-17 | — | — | EP | claimed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| US-7420060-B2 | Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containing them | SCHAEFFLER KG (DE) | 2008-09-02 | — | — | US | disclosed |
| US-7414068-B2 | Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2008-08-19 | — | — | US | disclosed |
| US-7309793-B2 | Benzopyran derivatives substituted with a benzimidazole derivative, pharmaceutically acceptable salts therof, their preparations and pharmaceutical compositions containing them | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2007-12-18 | — | — | US | disclosed |
| US-20070093481-A1 | Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containingthem | DONGBU HANNONG CHEMICAL CO., LTD. (KR) | 2007-04-26 | — | — | US | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| EP-0501797-B1 | Pyranyl cyanoguanidine derivatives | SQUIBB & SONS INC (US) | 1996-06-05 | — | — | EP | disclosed |
| US-5502220-A | Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-03-26 | — | — | US | disclosed |
| EP-0629619-A1 | Process for the preparation of intermediates useful in the preparation of pyranyl cyanoguanidine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0624589-A2 | Intermediates useful in the preparation of pyranyl cyanoguanidine derivatives and methods of preparing same | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-17 | — | — | EP | disclosed |
| US-5262419-A | Antiulcer agents | E. R. SQUIBB & SONS, INC. (US) | 1993-11-16 | — | — | US | disclosed |
| US-5140031-A | Pyranyl cyanoguanidine derivatives | E. R. SQUIBB & SONS, INC. (US) | 1992-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885ABCB1 1406/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885ABCB1 1229/4885 |
| US-20070093481-A1 | Benzopyran derivatives substituted with a thioxobenzoxazole derivative, pharmaceutically acceptable salts thereof, their preparations and pharmaceutical compositions containingthem | TNNT2, TNNI3, BRIX1 | ABCC9 221/4885ABCB1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.